Vodis Pharmaceuticals Inc.
Vodis Pharmaceuticals Inc. is positioned to be among the first pharmaceutical corporations in Canada to produce and market medical marijuana under license from Health Canada in accordance with the existing Narcotic Control Regulations (“NCR”) and the new Marihuana for Medical Purposes Regulations (“MMPR”) that came into effect on April 1, 2014. Vodis filed its MMPR in August 2013 and in January 2014 received a ‘ready to build’ letter from Health Canada. IT IS CURRENTLY AWAITING FINAL INSPECTION FROM HEALTH CANADA. The company has been operating under the MMAR regulations at its 12,000 square foot production facility consisting of six rooms. This was recently upgraded to eight rooms consisting of between 40 and 50 lights per room. The estimated production when fully operational under the MMPR license is between 150-200 pounds per month of award-winning cannabis.
Vodis Pharmaceuticals Inc. (VP)
December 19, 2016
Vodis Pharmaceuticals Inc. has announced a consolidation of its issued and outstanding share capital on the basis of one (1) post consolidation share for each four (4) pre-consolidation common shares. No fractional shares will be issued. Any fraction of a share will be rounded down to the nearest whole number.
As a result, the outstanding shares of the company will be reduced to approximately 28,460,645.
The shares will begin trading on a consolidated basis and with a new CUSIP number on December 21, 2016.